Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|January 2, 2023
Impact of the COVID-19 Pandemic on Liver Cancer Staging at a Multidisciplinary Liver Cancer ClinicDaniel Li, Angela Y Jia, Jane Zorzi, et al.
Cancer Medicine|December 27, 2019
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancerMark Yarchoan, Chiung-Yu Huang, Qingfeng Zhu, et al.
The Journal of Clinical Investigation|July 20, 2021
Systemic inhibition of PTPN22 augments anticancer immunityWon Jin Ho, Sarah Croessmann, Jianping Lin, et al.
Cancer Immunology Research|March 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 CytokinesMari Nakazawa, Soren Charmsaz, Elsa Hallab, et al.
The Lancet. Oncology|October 22, 2024
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D'Alessio, Bernardo Stefanini, Julia Blanter, et al.
Nature Communications|November 12, 2024
Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trialMarina Baretti, Ludmila Danilova, Jennifer N Durham, et al.
Nature Communications|June 23, 2026
Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trialHejia Henry Wang, Amanda L Huff, S Daniel Haldar, et al.
Journal of Hepatology|February 7, 2026
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinomaJean-Charles Nault, Claudia Campani, Theo Z Hirsch, et al.
Journal of Hepatology|August 1, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaGeorge Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2025
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular CarcinomaJean-Charles Nault, Claudia Campani, Theo Z Hirsch, et al.
Pageof 14